The Latest Cardiac and Vascular News
Record Revenue of $429.8 Million and $143.3 Million for Full Year and Fourth Quarter 2019 Launch Commenced of VASCEPA® as First and Only Drug with Its New Cardiovascular Risk Reduction Indication Management to Host Conference Call at 4:30 p.m. ET Today DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) — […]
Westport, CT, Feb. 25, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the closing and funding of […]
CONSHOHOCKEN, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development of resmetirom. We initiated two Phase 3 studies in NASH: […]
FAIRWAY, Kan., Feb. 25, 2020 /PRNewswire/ — Artio Medical, Inc (Artio), a medical device company developing innovative products for peripheral vascular and neurovascular diseases, announced today the appointment of seasoned medical device industry executive Maria Sainz to its Board of Directors as an independent director. Sainz is currently the President and CEO of AEGEA Medical, a venture […]
Funding to support the Aria CV Pulmonary Hypertension System Feasibility Study Financing led by Xeraya Capital ST. PAUL, Minn.–(BUSINESS WIRE)–Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that it has completed a $31 million Series B round of financing to fund its first […]
CALGARY, Alberta, Feb. 25, 2020 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) provides the following update: On February 21, 2020, the Court Queen’s Bench of Alberta (the “Court”), after having heard the concerns raised by the Company with respect to an application by J.M. […]
Q4 2019 worldwide revenue of $257.9 million, up 10.6% as reported over Q4 2018 Q4 2019 core revenue on a comparable, constant currency basis* up 8.5% over Q4 2018 Q4 2019 GAAP loss per share was $(0.08), compared to GAAP EPS of $0.16 in Q4 2018 Q4 2019 non-GAAP EPS* […]
Rex Health Ventures and Orlando Health Ventures lead strong syndicate of new and existing investors AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, a medical technology company focused on products for aortic valve repair for the treatment of aortic insufficiency, announced today the initial closing of its Series C equity financing. Lead […]
Former CEO of Freeline Therapeutics, Ltd. has outstanding international drug development, commercialization expertise, with focus on rare disease, gene therapy PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that it has entered into an exchange agreement with three holders of the Company’s 3.25% Senior Convertible Notes due 2020 (the “Existing Notes”), pursuant to which these investors […]
